JavaScript is disabled for your browser. Some features of this site may not work without it.
Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
The SARS-COV-2 seroprevalence among oncology patients
Patients with cancer are presumed to be vulnerable to an increased risk of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe clinical outcomes due to
the immunocompromised state mediated by their underlying malignancies and therapy. The aim
of this study was to estimate the SARS-CoV-2 seroprevalence, following second to fourth waves
in solid tumour patients attending the Steve Biko Academic Hospital (SBAH) for diagnosis and
treatment of cancer. We used the single-prick COVID-19 IgG/IgM Rapid Test Cassettes to detect
SARS-CoV-2 IgG/IgM antibodies in 760 patients with solid tumours who were asymptomatic and
who had never tested positive for coronavirus disease 2019 (COVID-19). Out of the 760 patients,
277 were male (36.4%), 483 were female (63.6%), and the mean age was 55 years (range 18–92). The
estimated total seroprevalence was 33.2%. The seroprevalence status of the COVID-19 IgG/IgM
antibodies rose significantly from the second wave (11.3%) to the third (67.38%) and then the fourth
(69.81%) waves with roughly similar counts. A significant number of the seropositive patients were
asymptomatic to COVID-19 (96%). There was a higher rate of seropositivity in cancer patients with
hypertension (p < 0.05). Patients with breast, gynaecologic, and prostate cancers exhibited increased
SARS-CoV-2 seropositivity. Although oncology patients may be susceptible to SARS-CoV-2 infection,
our data indicate that these patients remained asymptomatic throughout various waves with an
overall COVID-19 IgG/IgM antibody seropositivity of 33.16%, suggesting no risk of severe or fatal
cases of COVID-19.
Description:
DATA AVAILABILITY STATEMENT : Data supporting reported results can be requested by email from both corresponding authors.